GSK (LSE:GSK) declared another 17p quarterly Dividend on 28 October alongside third-quarter results that kept its full-year guidance intact. Under chief executive Luke Miels the drugmaker is now pointing to a 70p total payout for 2026, a clear step up from last year's figure. Income investors will be asking how much further that can go while the group's vaccines Business continues to struggle.

The income numbers

As of 7 October 2026, GSK's annual dividend stood at 66.0p per share and its latest quarterly payment at 17.0p. The trailing 12-month Yield is 3.9% and the indicated yield 4.0%. Dividend growth over the past year was 8.2%. The third-quarter announcement matched that 17p figure, and the expected 70p total for 2026 is about 6% ahead of the 66.0p annual figure.

The history requires some interpretation. GSK has paid dividends for 41 consecutive years, but it has raised them for only two years in a row. That short streak dates from the reset that accompanied the demerger of its consumer healthcare business, Haleon (LSE:HLN), in 2022, when the dividend was deliberately rebased. Investors who remember the old 80p payout should recognise that the current figure comes from a smaller, more focused company.

GSK pays its dividend in four quarterly instalments, which spreads the Cash Flow for shareholders through the year. The yield figures describe the payout relative to the share price at a point in time, so they will drift as the price moves even when the dividend itself is unchanged.

Comfortable cover

A trailing Payout Ratio of 56.8% implies dividend cover of about 1.8 times, a comfortable position for a pharmaceutical group. Cover is simply Earnings divided by the dividend, so a ratio below 100% means profits exceed the cash handed to shareholders, and the remainder can be reinvested. That gives the board room to keep lifting the dividend while still funding R&D and acquisitions. It also offers a cushion against the setbacks that are an unavoidable part of pharmaceutical investing.

The third quarter underlined why that cushion matters. Reported Earnings Per Share fell 23% to 38.5p at actual exchange rates, mainly because of £328m in restructuring charges from the group's Accelerate Growth programme. Core earnings per share, which strip out such items, were 54.6p, down 1% at actual rates and up 1% at constant currency. On that basis the 17p dividend was covered more than three times in the quarter.

The gap between reported and core figures is worth understanding. Reported earnings include restructuring costs, legal items and the Amortisation of acquired assets, while core earnings are designed to show the underlying trading picture. Dividend decisions at large drugmakers tend to look through one-off charges, but repeated restructuring costs can eventually erode the cash available, so investors tend to monitor both measures.

Another point of context is the relationship between the dividend and the wider Capital allocation framework. Cash generated by the business is shared between the dividend, Investment in the pipeline, bolt-on acquisitions and Balance Sheet management. A payout that rises faster than earnings leaves less for those other uses, so the planned increase to 70p is best read alongside the 7% to 9% growth guidance for core earnings per share, which broadly supports a rising distribution if delivered, though currency movements and one-off items can narrow that margin.

Specialty medicines carry the load

Group sales in the third quarter came to £8.9bn, up 4% at actual exchange rates and 5% at constant currency. Specialty Medicines was the best performer, with sales up 15% to £3.9bn, driven by HIV at £2.1bn and by oncology, which rose 23% to £0.6bn.

Vaccines were the weak spot. Sales fell 2% to £2.6bn, with Shingrix down 5% to £0.8bn and the respiratory syncytial virus Vaccine Arexvy down 24% to £0.2bn, though meningitis vaccines grew 12%. General Medicines were flat at £2.4bn.

Management reaffirmed its 2026 guidance for turnover growth of 3% to 5% and for growth of 7% to 9% in both core operating profit and core earnings per share. It also repeated its ambition for sales of more than £40bn by 2031. Recent approvals include Hibsago for chronic hepatitis B in the US and Japan, and an expanded use for Jemperli in the US in a form of rectal cancer.

Why the pipeline underpins the payout

A pharmaceutical dividend is only as durable as the medicines that fund it. Patents expire, competitors arrive and Demand for individual products can change quickly, so the long-term sustainability of the payout depends on a steady Supply of new treatments replacing older ones. That is why late-stage development news carries so much weight in the assessment of a company like GSK (LSE:GSK).

The mix of the business is shifting towards specialty medicines, where growth has been faster, while vaccines, historically a major earnings contributor, face pressure. Declines in Shingrix and Arexvy show how a single product category can move from tailwind to headwind. Because specialty products such as HIV treatments and oncology drugs are growing from a large base, they are doing much of the work of keeping group growth positive and, indirectly, of supporting the dividend.

What to watch

The full-year results early next year should confirm the 70p dividend and may give an early indication of the payout for 2027. Investors will watch whether vaccine sales stabilise, particularly Shingrix and Arexvy, which both declined in the third quarter. Progress on restructuring will also be under scrutiny, since those costs are depressing reported earnings.

GSK plans 22 phase III trial starts during 2026 and has begun 18 so far, so late-stage pipeline news will influence how confidently the market views the longer-term growth that would sustain further dividend increases. For shareholders of GSK (LSE:GSK), the central question is whether growth in specialty medicines and new approvals can more than offset the pressure on vaccines.